The trial will test DNA IL-12 administered using OncoSec’s novel treatment approach for immunotherapy (referred to as OMS ElectroImmunotherapy), in patients with local and distant MCC.
The trial is designed to assess the clinical and biologic effects of increased local expression of IL-12 protein in the tumor microenvironment following treatment with OMS ElectroImmunotherapy.
OncoSec president and CEO Punit Dhillon said the new clinical study is the only active immunotherapy trial that is focused specifically on this disease.